Boston Scientific bumps Mike Mahoney to top spot

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Boston Scientific bumps Mike Mahoney to top spot

Boston Scientific ($BSX) is gearing up for a changing of the guard. Interim CEO Hank Kucheman will step down Nov. 1, and then President Mike Mahoney--a veteran executive previously at Johnson & Johnson ($JNJ)--will finally take the top spot, capping a transition plan first laid out a year ago. Kucheman gave an exit interview of sorts to The Boston Globe, explaining that the major acquisitions, layoffs and restructuring that have taken place under his relatively short tenure are all part of a master plan: helping the struggling device company diversify and respond to a rapidly changing health care universe. Story

Mike Mahoney--Boston Scientific
Mahoney will replace CEO Hank Kucheman on Nov. 1.

Christian Weyer--Fate Therapeutics
Weyer will serve as president and CEO.

Christian Itin--Cytos Biotechnology
Itin will serve as CEO.


> Fate Therapeutics named Christian Weyer president and CEO. Release

> Cytos Biotechnology appointed Christian Itin as CEO. Itin served as CEO at Micromet for 8 years until the company was acquired by Amgen ($AMGN) earlier this year. Report

> Ceres ($CERE) announced that Richard Flavell will transition from his position as chief scientific officer and an executive officer of the company to a new role of chief scientific adviser. Release

> Theratechnologies announced that John-Michel T. Huss left his roles as president, CEO and a director of the company. Release

> Osmotica Pharmaceutical appointed Praveen Tyle as executive vice president and chief scientific officer. Release

> Steven W. Peterson, vice president and CFO of Mesa Laboratories ($MLAB), will retire Nov. 30. John V. Sakys will join the company Oct. 29 as executive vice president and the board of directors intends to eventually appoint Sakys as CFO. Release

> Promedior appointed Elizabeth Trehu as chief medical officer. Release

> Durata Therapeutics ($DRTX) named Allison Wey as vice president of investor relations and public affairs. Release

> NovAlix appointed Dr. Luc Van Hijfte as chief scientific officer. Release

> Dr. Joel Martin was newly named as Cebix CEO. Story

> Cerecor announced the appointment of James Vornov as senior vice president of clinical development and regulatory affairs, and John Kaiser as vice president of commercialization and business development. Release

> GnuBIO announced that Susie Truong Harborth will serve as CFO. Release

> A.P. Pharma appointed Robert Rosen as senior vice president and chief commercial officer. Release

> Aerie Pharmaceuticals appointed Richard J. Rubino as CFO. Release

> Caprotec Bioanalytics appointed Jonathan Turner as managing director and CEO. Release


> Amgen appointed Cynthia Patton as senior vice president and chief compliance officer. Release

> Simcere Pharmaceutical Group ($SCR) announced the resignation of Gary Siu Kwan Sik, an independent director of the company. Release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.